05 Set medication sales rep
Revenues for the French pharmaceutical industry reached 28.7 billion euros last year.
up 2.1%. An increase mainly due to the market for hospital medicines.
The pharmaceutical companies (Leem) have just presented their annual balance sheet.
They announce an increase of their turnover of 2.1% to reach 28.7 billion euros.
This increase is mainly due to growth in the hospital market, which rose by 7.5% compared to 2015.
“This growth is partly driven by drugs in ATU (temporary use) and post-ATU, a particularly dynamic segment in 2016.
This marks the arrival of a new wave of innovation, particularly in the field of oncology, “stresses the Leem. Refundable and non-refundable drugs
The market for reimbursable medicines saw its sales remain stable between 2015 and 2016, while volumes posted a slight decline of 0.2%.
Non-refundable medicines represent a market of 2.1 billion euros, up 1.7%, while in units this market falls by 1.3% compared to 2015.
The generic market
In August (2017)
Today, more than one in three (35.6%) drugs is generic. This market represents 5.5 billion euros of turnover (2.0 billion for the princeps and 3.5 billion for the generics).
Or, 30% of the reimbursable market. The sale of generic medicines resulted in savings of 2.2 billion euros in 2016 alone and would have generated nearly 22 billion euros in savings since 2000.
Drugs that are exported
French exports of medicines are on the increase compared to 2015. They reached 25.8 billion euros (+ 0.8%), after a year 2015 which had also grown by 2.2% compared to 2014. This year, the United States is the largest destination for French exports (up 8% in one year), followed by Germany and Belgium.
However, of the 282 new medicines authorized in Europe between 2012 and 2016, only
21 are produced in France, while Germany produces 86, the United Kingdom 68 and Italy 38